scispace - formally typeset
M

Michele Caraglia

Researcher at Seconda Università degli Studi di Napoli

Publications -  562
Citations -  24508

Michele Caraglia is an academic researcher from Seconda Università degli Studi di Napoli. The author has contributed to research in topics: Cancer & Cancer cell. The author has an hindex of 67, co-authored 525 publications receiving 20615 citations. Previous affiliations of Michele Caraglia include Temple University & Magna Græcia University.

Papers
More filters
Journal ArticleDOI

DTNQ-Pro, a Mimetic Dipeptide, Sensitizes Human Colon Cancer Cells to 5-Fluorouracil Treatment

TL;DR: This study evaluated whether a decrease of stress proteins induced by DTNQ-Pro in Caco-2 cells could sensitize these cells to treatment with 5-fluorouracil (5-FU) cytotoxicity, which could cause the sensitization of cancer cells to the cytot toxicity mediated by 5-FU.
Journal ArticleDOI

New Therapeutic Opportunities from Old Drugs: The Role of Nanotechnology?

TL;DR: This article was originally published in a journal by OMICS Publishing Group, and the attached copy is provided by the author for the author's benefit and for the benefit of the author’s institution.
Journal ArticleDOI

Exploring the efficacy and safety of single-agent sorafenib in a cohort of Italian patients with hepatocellular carcinoma.

TL;DR: Although the retrospective design of this study does not allow reaching any definite conclusion, the results could lend some preliminary support to the safety and the effectiveness of sorafenib monotherapy in patients with Child–Pugh B and Child-Pugh C liver function.
Journal ArticleDOI

HtrA1 loss is related to aggressive behavior parameters in sentinel node positive breast cancer.

TL;DR: Low HtrA1 expression is significantly related to breast cancer poor prognosis parameters, and H trA1 loss in sentinel nodes is related to metastasis of non sentinel node, offering a further marker useful for BC prognostic stratification.
Journal ArticleDOI

Prognostic significance of cxcr4 in colorectal cancer: An updated meta-analysis and critical appraisal

TL;DR: In this paper, the authors provided an updated estimate of the prognostic power of C-X-C chemokine receptor type 4 (CXCR4) in colorectal cancer (CRC), and analyzed modalities of evaluating and reporting its expression.